Canada markets closed

Sensei Biotherapeutics, Inc. (SNSE)

NasdaqGM - NasdaqGM Delayed Price. Currency in USD
Add to watchlist
0.6580-0.0170 (-2.52%)
At close: 04:00PM EDT
0.6364 -0.02 (-3.28%)
After hours: 05:06PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close0.6750
Open0.6890
Bid0.6274 x 100
Ask0.6917 x 100
Day's Range0.6000 - 0.6890
52 Week Range0.5100 - 1.9400
Volume92,313
Avg. Volume253,544
Market Cap16.503M
Beta (5Y Monthly)0.05
PE Ratio (TTM)N/A
EPS (TTM)-1.2100
Earnings DateAug 01, 2024 - Aug 05, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.25
  • GlobeNewswire

    Sensei Biotherapeutics to Participate in Jefferies Global Healthcare Conference

    BOSTON, May 30, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that John Celebi, President and Chief Executive Officer, will present at the Jefferies Global Healthcare Conference, being held in New York, NY, on Thursday, June 6, 2024 at 8:30 a.m. ET. A webcast of Sensei’s presentation will be available in the Investors secti

  • GlobeNewswire

    Sensei Biotherapeutics Presents Promising Clinical Data from Phase 1 Dose Escalation Study of SNS-101

    - Once every 3-week dosing of SNS-101 demonstrates initial signs of promising clinical activity - - Pharmacokinetic and safety profile validate conditionally active approach - - Investor webcast to be held on Monday, June 3 at 8:00 a.m. ET - BOSTON, May 23, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported encouraging clinical d

  • GlobeNewswire

    Sensei Biotherapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

    - Completed SNS-101 monotherapy and combination dose escalation through 15mg/kg with no dose limiting toxicities - - Company to present topline clinical data from the SNS-101 Phase 1 dose escalation study at the 2024 ASCO Annual Meeting - - Enrollment in the dose expansion portion of the clinical study advancing - - Strong balance sheet with cash runway into fourth quarter of 2025 - BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-onco